Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc V.VIV.H

Alternate Symbol(s):  VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


TSXV:VIV.H - Post by User

<< Previous
Bullboard Posts
Next >>
Post by DrJayseron Mar 17, 2023 4:01pm
289 Views
Post# 35345904

The company reported net revenues of $66,039

The company reported net revenues of $66,039The company reported net revenues of $66,039 and a comprehensive loss of $(1,153,930) for the three-month period ending Jan. 31, 2023. This compares with revenues of $271,157 and a comprehensive loss of $(1,552,852) in the three-month period ending Jan. 31, 2022. As at Jan. 31, 2023, the company reported total assets of $568,302 (current assets of $494,409), total liabilities of $7,678,343 and shareholders' deficit of $(7,110,041).
<< Previous
Bullboard Posts
Next >>